Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.86 HKD | +2.12% | +17.68% | -8.96% |
May. 28 | Hong Kong Stocks Stayed Flat Despite Shanghai’s Property Cuts, Beijing’s Huge Investment Plan | MT |
May. 28 | Alibaba Health Shares Rise on Earnings Beat | DJ |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 72.91 times its estimated earnings per share for the ongoing year.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-8.96% | 7.95B | B | ||
-35.29% | 10.33B | B | ||
+4.90% | 5.86B | C | ||
-14.10% | 5.71B | C+ | ||
+70.58% | 4.5B | C | ||
-4.09% | 4.55B | D- | ||
-8.29% | 3.77B | B | ||
-22.05% | 3.05B | C- | ||
-13.61% | 2.81B | C- | ||
-11.32% | 2.57B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 241 Stock
- Ratings Alibaba Health Information Technology Limited